Med Spa Manufacturer Loyalty Programs: What Allē, ASPIRE, Xperience+ and Evolus Rewards Actually Publish

On 20 August 2026 we read the Allē document that actually contains the earning rules, and it is not the one most often quoted. The Allē Eligible Products, Program Points, and Earning Caps page, updated 01/06/2026, carries a "Non-Allergan Aesthetics Products Table." It lists Dysport, Daxxify, Xeomin, Letybo and Jeuveau. It also lists Wegovy, Ozempic, Mounjaro, Zepbound and "Compounded GLP-1." Each is an Earnings Eligible Product at 50 points per treatment.

The two Allē documents usually reached for instead are the Allē Consumer Loyalty Program Terms and Conditions and the consumer "How Allē Works" page. The Allē Consumer Loyalty Program Terms and Conditions, read on 20 August 2026, contains no earning table, and the "How Allē Works" page, read on 20 August 2026, contains no earning table either. The Terms say as much themselves, in a sentence that sends you to a third document.

The half that gets left out is the second column. That same table has a "Redemption Eligible Product(s)" column. Every Allergan Aesthetics product reads "Yes." The row for a non-Allergan product reads "No."

Meanwhile AbbVie's own SEC filings name customer loyalty program changes as a pricing driver, first in a list of causes, across three consecutive filings and in both directions.

This post reads the four US manufacturer programs from their own published documents: what earns, what expires and when, what is capped, what the manufacturer requires of your purchasing, and what each company publishes about the practice side.

Every source on this page was read on 20 August 2026. We make med spa software, so we have an obvious interest in how practices track loyalty enrollment and redemption at check-in. The published program terms below hold regardless of whose software you run them in.

What AbbVie told the SEC about its own loyalty program

AbbVie's Form 10-K for fiscal year 2025, filed 20 February 2026, contains this sentence in Management's Discussion and Analysis:

In the United States, Botox Cosmetic net revenues decreased 11% primarily driven by unfavorable pricing due to customer loyalty program changes, lower market share and decreased consumer demand, partially offset by the timing of customer inventory destocking in the prior year.

Read the order of the drivers. Customer loyalty program changes are named first, ahead of market share and ahead of consumer demand. In the copy of that filing we read on 20 August 2026, the word "loyalty" appears exactly once in the whole document, so this is the only sentence of its kind in it.

Two numbers matter and they are not the same number. The narrative says the US line "decreased 11%." The revenue table in the same filing reports US Botox Cosmetic at $1,504 million for 2025 against $1,682 million for 2024, a change of (10.5)% on both the reported and the operational basis. Both the "decreased 11%" sentence and the percentage columns sit in Management's Discussion and Analysis, which is outside the audit opinion. MD&A narrative percentages track the operational basis, and for the US column reported equals operational here. Only the dollar figures are audited.

The consequence for an owner is practical. The economics of the rewards your patients chase are set by the manufacturer, described in its SEC filings, and revised on the manufacturer's own timetable. What a practice can act on is knowing which program document is current and what that document currently says.

The earning rules are not in the terms document

The Allē Consumer Loyalty Program Terms and Conditions, updated 06/17/2026 and carrying document code PRT128390-v15 04/26, read on 20 August 2026, contains no statement of what earns points. It points at a different file:

The Earnings Eligible Products, the amount of Base Points earned by Members for each, and any applicable limitations ... are stated in the Allē Eligible Products Program Points and Earnings Caps.

That second document is the eligible products and earning caps page, and the copy we read is marked "Updated: 01/06/2026." A single patient's economics are governed by two documents on two vintages about five months apart, and the one with the numbers in it is the older one.

If your front desk was trained from the Terms and Conditions, it was trained from a document that explicitly delegates the earning rules elsewhere. Any staff answer about what earns points, sourced from the Terms alone, comes from a file that does not contain the answer.

The consumer page adds a third vintage. How Allē Works, read the same day, states that "Allē Members earn points on over 50 aesthetic products and treatments" and that "Every 100 points gives you $10 toward qualifying brands or treatments." Its worked examples are one BOTOX Cosmetic treatment at 200 points or $20, two JUVÉDERM VOLUMA XC syringes at 400 points or $40, and one CoolSculpting Elite treatment at 500 points or $50. It is a useful page for a patient, and the "How Allē Works" page, read on 20 August 2026, contains no earning caps and no eligible products table.

What the Non-Allergan Aesthetics Products Table lists

The Non-Allergan Aesthetics Products Table lists competing neurotoxins and GLP-1 medications side by side, each earning 50 points per treatment. Dysport, Daxxify, Xeomin, Letybo and Jeuveau appear there. So do Wegovy, Ozempic, Mounjaro, Zepbound and "Compounded GLP-1."

Be precise about the mechanism. Points attach to a GLP-1 logged as a treatment at an Allē provider, not to filling a prescription at a pharmacy. The Terms require purchase "from a provider registered to participate in this Program," and the cap is stated per treatment "in accordance with the applicable Non-Allergan Aesthetics treatment label." The Allē Eligible Products, Program Points, and Earning Caps page and the Allē Consumer Loyalty Program Terms and Conditions, both read on 20 August 2026, contain no pharmacy-fill mechanism.

Then the column that changes the shape of the thing. In the Eligible Products Table, "Redemption Eligible Product(s)" reads "Yes" for every Allergan Aesthetics product. The row reading "Non-Allergan Aesthetics Product/Procedure listed in Non-Allergan Aesthetics Product Table" reads "No."

Stated plainly, and without inferring anyone's motive: a patient treated at your clinic with a competing toxin, or given a GLP-1 as a treatment, can accrue Allē points from that visit, and per the "Redemption Eligible Product(s)" column on the Allē Eligible Products, Program Points, and Earning Caps page updated 01/06/2026, those points are redeemable only against Allergan Aesthetics brands. The check-in that creates the balance happens at your front desk. That is a retention question before it is a purchasing question, because a live balance gives a patient an economic reason to rebook into one category.

Four programs, four different expiry clocks

All four programs describe expiry in months, and all four mean something different by it. Read from each company's own pages on 20 August 2026.

Allē and Merz both say twelve months and behave in opposite ways. Allē's clock runs from the date of last Program activity, so any qualifying visit pushes the whole balance forward. Merz's runs from the date earned, so each tranche runs out on its own schedule and today's visit does nothing for points earned last September. The Merz figures here are from the Xperience+ consumer program page, document code US-XPE-2500065, read on 20 August 2026.

ASPIRE runs two clocks in sequence. Points last 270 days from the date earned, and once converted at 100 points to $10, the reward lasts 60 days from the date issued. A patient who banks points and converts late can lose value at either gate. The ASPIRE Galderma Rewards FAQ, read on 20 August 2026, contains no effective date and no version marker, so that row is cited as published on the day we read it and nothing more.

Evolus Rewards has a floor as well as a ceiling. Its consumer terms, effective 1 August 2025, state the benefit "cannot be used prior to 90 days, and it cannot be used after 15 months," and that the amount is the one "set by Evolus." Club Evolus sits on an older vintage again, effective 1 July 2024: $49 per month for 20 units of Jeuveau every 90 days, "Units do not accrue if you wait more than 90 days between treatments," a $100 cancellation fee inside the first three months, and enrolment automatically opts the patient out of Evolus Rewards. If you sell your own plans, map that against how you price a membership, because one patient can sit inside two programs governed by documents a year apart.

The caps almost nobody quotes

"Over 50 products and treatments" is the consumer headline on the "How Allē Works" page. The earning caps page, updated 01/06/2026, is where the ceilings live.

Put the annual ceiling next to the tier gate and the cadence becomes calculable. The Terms state: "Members must earn at least 1,200 Base Points from January 1 to December 31 of a single year. Only Base Points are counted toward A-List tier status. Bonus Points do not qualify toward A-List membership." Against a 5,000 Base Point annual maximum, the gate is roughly a quarter of everything a patient can possibly earn in a year.

That "Base" qualifier does real work, and Allē's own two pages differ on it. The consumer "How Allē Works" page describes the requirement as earning 1,200 points in a calendar year, without the word Base. The Terms, updated 06/17/2026, add that bonus points do not count. A patient stacking a double points promotion, on the strength of the consumer page's wording, may be earning points that do not move the tier at all. Where the two Allē documents differ, the Terms and Conditions is the governing document and the consumer page is marketing copy.

The lifetime caps deserve their own note. The Allē consumer "How Allē Works" page, read on 20 August 2026, contains no lifetime caps; they appear only on the earning caps page. When a long-standing patient asks why a visit produced nothing, a lifetime ceiling reached three years ago is a possible answer, and it is invisible in your records unless you kept them.

What the manufacturer requires of your purchasing

The earning caps page sets a condition that binds the clinic, not the patient:

To earn Base Points on a treatment with an Earnings Eligible Product, the product used by the Allē Provider cannot be a product sample, the treatment must be performed using the listed brand-name Earnings Eligible Product purchased, for Allergan Aesthetics Earnings Eligible Products, the product must have been purchased directly from Allergan Aesthetics ...

The same page adds that "Program Points can only be earned and redeemed on cash-pay (ie, no government or private health plan reimbursement) procedures."

Three consequences follow from the published text. A sample vial used on a real patient does not produce points for that patient, so a goodwill gesture can cost a reward. Product not purchased directly from Allergan Aesthetics does not satisfy the stated condition, which means a sourcing decision made in your back office can surface later as a question at your front desk. And if any part of a procedure runs through insurance, the published rule places it outside the program.

The patient-facing view of this is thin. The patient sees a balance that did not move. The place the reason exists is your purchase record for the vial or syringe used, matched to the visit. That match is a record-keeping job, and it is the highest-value thing an owner can fix here.

What each program publishes about the practice side

All four companies publish something practice facing, in very different amounts. This is what was on their own pages on 20 August 2026.

Evolus publishes the most, and it publishes it across two documents rather than one. The conversion rates themselves are on the Evolus Provider Rewards page, read on 20 August 2026: patient check-ins become credits, and credits become product. The Evolus Practice Rewards Terms and Conditions, effective 1 August 2025 and carrying code US-UNB-2500295, set the form of the reward and the condition on it: the practice is compensated in Jeuveau vials and Evolysse syringes rather than cash, and "HCP Rewards have no independent monetary value and are only earned once all required Benefits are properly redeemed."

Read that clause slowly, because it sets the order of operations. The practice's reward is contingent on the patient actually redeeming, not on the patient enrolling and not on the treatment happening. A check-in that never converts into a redemption is, by the published terms, not yet a reward for the clinic.

For Merz and Allergan the direction of travel is published and the magnitude is not. The Merz professional loyalty and rewards page states that spend drives practice tier and that rebates are applied every six months. That page, and the Allergan Aesthetics provider resources page, both read on 20 August 2026, contain no thresholds and no percentages, so the only published route to your own position is the portal each company gives you.

How a manufacturer accounts for rewards it has issued

One company describes what unredeemed rewards do to its own books. Evolus, Inc.'s Form 10-K for fiscal year 2025, filed 3 March 2026, sets out the accounting:

The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation ... The significant estimates and assumptions used to establish the liability for the Reward are standalone selling price of the Reward and expected redemption rate by participating customers ... estimated based on historical data ... The portion of invoice price allocated to the Reward is initially recorded as deferred revenue.

Note the scope. Evolus's customers in that sentence are the practices, so this describes the practice-facing program rather than the patient one. The mechanism is disclosed. The Evolus FY2025 Form 10-K, read on 20 August 2026, contains no numeric redemption rate. For comparison, AbbVie's FY2025 Form 10-K, read on 20 August 2026, contains no occurrence of the word "breakage" and no occurrence of the word "unredeemed." Both of those are statements about those two filings on that date. Neither extends to Merz, which is private, or to Galderma, which is not an SEC filer.

The operator takeaway is not accounting. It is that an issued reward is a liability someone is carrying and estimating, that the estimate moves with redemption behaviour, and that redemption behaviour is scheduling. Scheduling is yours.

The 2026 reversal, in the same disclosure

The 2025 sentence is half the story, and quoting it alone would be selective. AbbVie's Form 10-Q for the quarter ended 31 March 2026, filed 8 May 2026, states in Management's Discussion and Analysis:

Net revenues for Botox Cosmetic increased 17% for the three months ended March 31, 2026 primarily driven by favorable pricing due to customer loyalty program changes in the United States in the prior year and the timing of customer inventory stocking.

Handle that 17% carefully, because it is easy to misquote. It is the total Botox Cosmetic line on the operational basis, not the US line. In the quarter's revenue table the US line reads $371 million against $295 million, and the total line reads $668 million against $556 million, which is 20.2% reported and 17.0% operational. As in the 10-K, the narrative sentence and the percentage columns are MD&A rather than audited statements. The same filing attributes part of the Juvederm Collection result to the same cause.

The Form 10-Q for the quarter ended 30 June 2026, filed 3 August 2026, continues it in the same MD&A section: "Net revenues for Botox Cosmetic increased 3% for the three months and 10% for the six months ended June 30, 2026," with the six month figure "also impacted by favorable pricing due to customer loyalty program changes in the United States in the prior year."

Same stated cause, named first among the decline drivers in one filing and among the recovery drivers in the next two. What the filings establish is that customer loyalty program changes are a factor AbbVie identifies and reports on, quarter after quarter, rather than something it treats as background. Programs that get reported on get revised, which is the argument for reading the current document rather than the one handed to you last year.

What your software has to do at check-in

None of this is actionable unless the visit record carries enough to reconstruct it later. Here is the vendor-neutral specification. Against the client record, at the visit, you need:

• Program enrollment per patient, per program. One patient can sit in several at once, and Club Evolus enrolment changes their Evolus Rewards status, so a single flag will not do.

• The product administered, by brand and by lot. The Allē condition turns on the specific brand-name product used.

• The purchase source for that product, tied to the vial or syringe.

• Units administered. A 20 unit floor and per-syringe counting cannot be rebuilt from a dollar total.

• Payment type. Cash-pay status is a published earning condition.

• Date of last qualifying activity per program. This is the field Allē's twelve month clock runs on.

• Points or credits captured, and the date issued for any reward. Two clocks, so two dates.

• Lifetime counters for the lifetime-capped products. An annual counter cannot answer a lifetime question.

With those fields present the recall list writes itself: Allē patients approaching eleven months since last activity, ASPIRE patients holding points past six months, Merz patients with a tranche earned around this date last year, Evolus patients past day 90 and inside month fifteen. That is a rebooking list built from published expiry rules rather than guesswork, and it belongs in whatever loyalty tracking you already run.

Do this next. Open each program's current document, note the version date printed on it, and set a calendar reminder for the first week of each quarter to check those four dates again. Then run one query against your own visit records for every patient treated in the last twelve months where brand administered, units and payment type are not all recorded. That list is the size of your blind spot, and it is the only number in this post you have to produce yourself.

Frequently asked questions

Does Allē award points for a competitor's neurotoxin?

Yes, according to the Allē Eligible Products, Program Points, and Earning Caps page updated 01/06/2026 and read on 20 August 2026. Its Non-Allergan Aesthetics Products Table lists Dysport, Daxxify, Xeomin, Letybo and Jeuveau as Earnings Eligible Products at 50 points per treatment. That rule is not in the Consumer Loyalty Program Terms and Conditions, which delegate earning rules to the separate document, which is why the question is so often answered from the wrong file.

Can a patient spend those points on the competitor's product?

No. The Eligible Products Table carries a "Redemption Eligible Product(s)" column. Every Allergan Aesthetics product reads "Yes." The row covering non-Allergan products listed in the Non-Allergan Aesthetics Product Table reads "No." Points accrued from a competing neurotoxin, or from a GLP-1 logged as a treatment at an Allē provider, are redeemable only against Allergan Aesthetics brands, at the published rate of 100 points to $10.

Do Allē points for a GLP-1 come from filling a prescription?

Not according to the documents we read on 20 August 2026. Wegovy, Ozempic, Mounjaro, Zepbound and "Compounded GLP-1" appear in the Non-Allergan Aesthetics Products Table at 50 points per treatment, but earning is stated per treatment in accordance with the applicable treatment label, and the Terms require purchase from a provider registered to participate in the program. The Allē earning caps page and the Allē Terms and Conditions, both read on 20 August 2026, contain no pharmacy-fill mechanism. The accurate description is a GLP-1 logged as a treatment at an Allē provider.

When do Allē points expire?

The Allē Consumer Loyalty Program Terms and Conditions, updated 06/17/2026, set two rules. For non-A-List members, "Any Program Points earned will expire twelve (12) months from the date of last Program activity." For A-List members, "Points do not expire for Members who continually maintain A-List membership." Because the non-A-List clock runs from last activity rather than from the date earned, one qualifying visit moves the entire balance forward.

What does a patient need to reach Allē A-List?

The Terms and Conditions state: "Members must earn at least 1,200 Base Points from January 1 to December 31 of a single year. Only Base Points are counted toward A-List tier status. Bonus Points do not qualify toward A-List membership." The consumer marketing page describes the same requirement without the word Base. Since the earning page caps total earning at 5,000 Base Points per calendar year, the gate is about a quarter of a patient's maximum possible annual earning.

How long do ASPIRE Galderma Rewards points last?

The ASPIRE Galderma Rewards FAQ, read on 20 August 2026, states that points "expire 9 months (270 days) after the date on which they were earned," and separately that ASPIRE Rewards, issued at 100 points to $10, "expire 60 days from the date issued." That is two sequential clocks on the same value. That page, read on 20 August 2026, contains no version marker and no effective date, so these facts are cited only as published on the day we read them.

Does buying product from a distributor affect my patient's points?

The Allē earning caps page states that to earn Base Points the product used "cannot be a product sample," that the treatment must use the listed brand-name Earnings Eligible Product purchased, and that for Allergan Aesthetics products "the product must have been purchased directly from Allergan Aesthetics." The same page limits earning and redemption to cash-pay procedures. Those are conditions on the practice, so your purchasing and payment records determine whether the patient's balance moves.

What does the practice itself receive from these programs?

It varies by company and by how much each publishes. Evolus publishes the most, across two documents. Its Practice Rewards Terms and Conditions, effective 1 August 2025, pay the practice in Jeuveau vials and Evolysse syringes, earned only once the patient's benefit is redeemed, with a ten vial or syringe same-or-previous-quarter purchase threshold. Its Provider Rewards page publishes the conversion rate, "1 Reward credit for every $40 patient checked in." Merz's professional page publishes spend-driven practice tiers and rebates applied every six months, without thresholds or percentages. Allergan Aesthetics names Allergan Partner Privileges and Allē reimbursements through its Advantage platform, without rebate percentages, tier names or thresholds.